Evidence map›Paper›PMID 30987105›Full record

ArticleInternational journal of molecular sciences2019

Proinsulin C-Peptide Enhances Cell Survival and Protects against Simvastatin-Induced Myotoxicity in L6 Rat Myoblasts.

Sumia Mohamed Essid, Alan Bevington, Nigel J Brunskill

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sumia Mohamed EssidDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 7 RH, UK. s.essid@uq.edu.au.
Alan BevingtonDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 7 RH, UK. ab74@le.ac.uk.
Nigel J BrunskillDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 7 RH, UK. njb18@leicester.ac.uk.ORCID 0000-0002-7109-7108
University of Leicester · GB

Funding

Medical Research Council G0500688
6 · The paper itself

Abstract

The repair capacity of progenitor skeletal muscle satellite cells (SC) in Type 1 diabetes mellitus (T1DM) is decreased. This is associated with the loss of skeletal muscle function. In T1DM, the deficiency of C-peptide along with insulin is associated with an impairment of skeletal muscle functions such as growth, and repair, and is thought to be an important contributor to increased morbidity and mortality. Recently, cholesterol-lowering drugs (statins) have also been reported to increase the risk of skeletal muscle dysfunction. We hypothesised that C-peptide activates key signaling pathways in myoblasts, thus promoting cell survival and protecting against simvastatin-induced myotoxicity. This was tested by investigating the effects of C-peptide on the L6 rat myoblast cell line under serum-starved conditions. Results: C-peptide at concentrations as low as 0.03 nM exerted stimulatory effects on intracellular signaling pathways-MAP kinase (ERK1/2) and Akt. When apoptosis was induced by simvastatin, 3 nM C-peptide potently suppressed the apoptotic effect through a pertussis toxin-sensitive pathway. Simvastatin strongly impaired Akt signaling and stimulated the reactive oxygen species (ROS) production; suggesting that Akt signaling and oxidative stress are important factors in statin-induced apoptosis in L6 myoblasts. The findings indicate that C-peptide exerts an important protective effect against death signaling in myoblasts. Therefore, in T1DM, the deficiency of C-peptide may contribute to myopathy by rendering myoblast-like progenitor cells (involved in muscle regeneration) more susceptible to the toxic effects of insults such as simvastatin.

Indexed as

AnimalsCaspase 3Cell DeathCell LineCell ShapeCell SurvivalC-PeptideEnzyme ActivationExtracellular Signal-Regulated MAP KinasesMuscle, SkeletalMuscular DiseasesMyoblastsProto-Oncogene Proteins c-aktRatsReactive Oxygen SpeciesSignal TransductionCaspase 3C-PeptideExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSimvastatinmyotoxicityproinsulin C-peptidesimvastatinType 1 diabetes

Identifiers

PMID30987105
PMCPMC6479794
OpenAlexW2932116270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.